GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.

Zacks Investment Research • Aug 20, 2026

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.

Zacks Investment Research • Aug 19, 2026

Glaukos Announces Participation in Wells Fargo Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors.

Business Wire • Aug 19, 2026

Glaukos Q2 Earnings Call Highlights

Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management's expectations.

MarketBeat • Jul 30, 2026

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

Zacks Investment Research • Jul 30, 2026

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 30, 2026

Glaukos Announces Second Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include: Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis. Glaucoma record ne.

Business Wire • Jul 29, 2026

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.24 per share a year ago.

Zacks Investment Research • Jul 29, 2026

Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Jul 30, 2026

Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 Release

Glaukos Corporation remains rated "Hold" as shares approach technical resistance near $160 ahead of the Q2 earnings release. Strong revenue growth—41%+ in Q1 and 38% YoY in Q3—has driven recent upgrades and fueled a 91% stock rally since last year. Key catalysts include potential Q2 revenue outperformance, guidance hikes above $640 million, and robust uptake of Epioxa and iDose TR.

Seeking Alpha • Jul 28, 2026